Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CWBR NASDAQ:EVFM NASDAQ:NCNA NASDAQ:NMTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AEVFMEvofem Biosciences$0.01+3.2%$0.01$0.01▼$0.02$1.15M-0.92429,920 shs115,216 shsNCNANuCana$0.12+106.8%$0.13$0.03▼$10.79$632K1.4240.44 million shs224.95 million shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWBRCohBar0.00%0.00%0.00%0.00%+64.00%EVFMEvofem Biosciences-5.05%-5.05%-2.08%+4.44%-14.55%NCNANuCana+11.42%-8.10%+11.42%-92.59%-98.09%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem Biosciences0.5975 of 5 stars0.03.00.04.80.00.00.0NCNANuCana2.5188 of 5 stars3.32.00.00.01.12.51.3NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWBRCohBar 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0021,639.13% UpsideNMTR9 Meters Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00NCNANuCanaN/AN/AN/AN/A$1.34 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/ANCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ALatest NCNA, CWBR, EVFM, and NMTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWBRCohBarN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWBRCohBarN/AN/AN/AEVFMEvofem BiosciencesN/A0.110.09NCNANuCanaN/A1.251.25NMTR9 Meters BiopharmaN/A0.590.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWBRCohBar2.47%EVFMEvofem Biosciences0.22%NCNANuCana44.00%NMTR9 Meters Biopharma22.34%Insider OwnershipCompanyInsider OwnershipCWBRCohBar6.51%EVFMEvofem Biosciences0.21%NCNANuCana31.20%NMTR9 Meters Biopharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCWBRCohBar102.91 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataNCNA, CWBR, EVFM, and NMTR HeadlinesRecent News About These CompaniesWhat is a prepayment meter?August 24, 2024 | uswitch.comUAfter coeliac fail, 9 Meters plots phase 3 in short bowel syndromeJuly 28, 2024 | pharmaphorum.comPEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comBDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.com9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.comTRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 secondsOctober 28, 2023 | asahi.comA9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.comVintage Meters Reborn As Steam Punk ClockOctober 10, 2023 | hackaday.comH9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comInsider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?July 25, 2023 | knoxdaily.comK9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock ValueJuly 21, 2023 | knoxdaily.comKRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comWhy Are 9 Meters Biopharma Shares Nosediving Today?July 18, 2023 | finance.yahoo.comExamining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)July 18, 2023 | knoxdaily.comKTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | bizjournals.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 30, 2023 | finance.yahoo.com9 Meters Biopharma (NASDAQ: NMTR)May 27, 2023 | fool.comNMTR - 9 Meters Biopharma, Inc.May 25, 2023 | uk.finance.yahoo.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 19, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, CWBR, EVFM, and NMTR Company DescriptionsCohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Evofem Biosciences NASDAQ:EVFM$0.0097 +0.00 (+3.19%) As of 10:07 AM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.NuCana NASDAQ:NCNA$0.12 +0.06 (+106.83%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
